Home > Neurology > EAN 2020 > Multiple Sclerosis > High NEDA rates after 2 years of ocrelizumab

High NEDA rates after 2 years of ocrelizumab

In the CASTING open-label single-arm prospective trial of ocrelizumab, the proportion of patients with no evidence of disease activity (NEDA) at year 2 was high: 74.8%–80.4% of patients were free of clinical disease activity, while 91.5% of patients were free of MRI activity [1]. NEDA was maintained from year 1 over year 2.

CASTING is a phase 3b study evaluating the efficacy and safety of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) patients with suboptimal response to 1 or 2 prior disease-modifying treatments (DMTs). The intention-to-treat (ITT) population included 680 patients. After 2 years, 74.8% of patients had NEDA; 80.4% had no evidence of clinical activity, 91.5% had no evidence of MRI activity, and 89.8% had no relapses.

The exploratory endpoint of 2-year NEDA with MRI from screening was reached by 52.0% of patients. This lower percentage was mainly due to the low...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on